Sirolimus for epileptic seizures associated with focal cortical dysplasia type II

Mitsuhiro Kato1, Akiko Kada2, Hideaki Shirashi3, Jun Tohyama4, Eiji Nakagawa5, Yukitoshi Takahashi6, Tomoyuki Akiyama7, Akiyoshi Kakita8, Noriko Miyake9,10, Atsushi Fujita9, Akiko M. Saito2 & Yushi Inoue6

1Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
2Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
3Department of Pediatrics, Hokkaido University Hospital, Sapporo, Japan
4Department of Child Neurology, National Hospital Organization Nishinigata Chuo Hospital, Niigata, Japan
5Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan
6National Hospital Organization, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
7Department of Child Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
8Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan
9Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
10Department of Human Genetics, Research Institute National Center for Global Health and Medicine, Tokyo, Japan

Abstract

Objective: To determine whether sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, reduces epileptic seizures associated with focal cortical dysplasia (FCD) type II. Methods: Sixteen patients (aged 6–57 years) with FCD type II received sirolimus at an initial dose of 1 or 2 mg/day based on body weight (FCDS-01). In 15 patients, the dose was adjusted to achieve target trough ranges of 5–15 ng/mL, followed by a 12-week maintenance therapy period. The primary endpoint was a lower focal seizure frequency during the maintenance therapy period. Further, we also conducted a prospective cohort study (RES-FCD) in which 60 patients with FCD type II were included as an external control group. Results: The focal seizure frequency reduced by 25% in all patients during the maintenance therapy period and by a median value of 17%, 28%, and 23% during the 1-, 4-, 5-, and 9–12-week periods. The response rate was 33%. The focal seizure frequency in the external control group reduced by 0.5%. However, the background characteristics of external and sirolimus-treated groups differed. Adverse events were consistent with those of mTOR inhibitors reported previously. The blood KL-6 level was elevated over time. Interpretation: The reduction of focal seizures did not meet the predetermined level of statistical significance. The safety profile of the drug was tolerable. The potential for a reduction of focal seizures over time merits further investigations.

Introduction

Fewer than 20% of patients with focal cortical dysplasia (FCD) have transient responsiveness to pharmacotherapy, and most require surgical resection of the brain lesion. However, epilepsy surgery for FCD is one of the most challenging procedures because lesions are commonly located in the functional cortical area and have an uncertain demarcation in the epileptogenic zone on magnetic resonance imaging (MRI) and electroencephalogram (EEG). Approximately one-third of patients still present with seizures after surgical resection with comprehensive neuroimaging and electrophysiological evaluations. Somatic mutations in the mechanistic target of rapamycin (mTOR) and other genes correlated with the mTOR signaling pathway, such as AKT3 and PIK3CA,
have been identified in the pathological brain tissues of patients with FCD type IIa or IIb. MTOR is the most frequent causative gene for FCD IIa or IIb and the second common causative gene for hemimegalencephaly (Table S1). These mutations cause the elevated activation of mTOR signaling, which is a major cause of FCD type II. The intrinsic epileptogenicity of FCD itself has been confirmed via intraoperative electrocorticography and stereo-EEG. Sirolimus or rapamycin is an mTOR inhibitor, which has suppressed epileptic seizures in an FCD model of mice with hyperactivated mutant mTOR. This drug is beneficial for the treatment of seizures in animal models of genetic mTOR hyperactivation and in patients with tuberous sclerosis complex (TSC) caused by TSC2 or TSC1 mutation leading to mTOR hyperactivation. Additionally, reduction in seizure frequency has been reported in a patient with hemimegalencephaly due to a somatic mosaic MTOR mutation (Table S2). We conducted a single-center clinical trial (as a proof-of-concept study) to validate the effect of sirolimus on seizure control in a small number of patients with FCD type II in 2018. Results showed that sirolimus was beneficial for treating seizures in patients with FCD (manuscript submitted). Herein, we report the results of the first single-arm, open-label, multicenter clinical trial that assessed the efficacy and safety of sirolimus for the treatment of epileptic seizures in patients with FCD type II (FCDS-01).

### Methods

#### Study design and participants

We conducted this investigator-initiated, single-arm, open-label, multicenter trial at five institutions in Japan between December 2018 and August 2020. The trial rationale and design have been described previously. Patients aged 6–65 years who were diagnosed with FCD type II via brain MRI in accordance with the radiological criteria or histopathological findings were eligible. All patients had focal onset seizures, including focal to bilateral tonic–clonic seizure, at a frequency of more than twice in a 28-day baseline phase (Fig. 1). All patients had a treatment history of more than two antiepileptic drugs for at least 52 weeks after epilepsy diagnosis and were receiving one to four concomitant antiepileptic drugs. The dose and regimen of concurrent antiepileptic drugs were sustained from the 8th week before study enrollment. We excluded patients with a history of undergoing neurosurgical procedures within 28 weeks prior to enrollment with consideration of other treatment protocols including antiepileptic drugs.

#### Standard protocol approvals, registrations, and patient consents

The research protocol was approved by the central ethics review committee for clinical research of the National Hospital Organization and the institutional review board of each institution (FCDS-01). An independent data and safety monitoring board reviewed the trial progress. Written informed consent was obtained from all patients or their legal guardians prior to study enrollment. Able patients under 16 years provided consent. This study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000033504).

#### Study medication and procedures

Patients with a body weight of <40 and ≥40 kg received oral sirolimus as a tablet at an initial dose of 1 and 2 mg/day, respectively, once a day. The dose was adjusted to achieve the target blood trough levels (range: 5–15 ng/mL) during the 8–24-week titration period (dose-adjustment phase). If the concentrations were <5 ng/mL, the daily sirolimus dosage was increased by 1 mg every 2 weeks until the 8th week, and then every 4 weeks until the 24th week. From the time when the trough concentration reached the target range, or after 24 weeks if the trough concentration did not reach the target range, 12-week maintenance therapy was started. The participants visited the hospitals at 4, 8, and 12 weeks during the maintenance therapy period. No further adjustments were made during this period unless medication-related adverse events required treatment, discontinuation, or dosage adjustment to half of the current dose.

#### Trial outcomes

The primary endpoint was a reduced frequency of focal seizures (including focal to bilateral tonic–clonic seizures), which is a main seizure type in patients with FCD, per 28 days during the maintenance therapy period. Patients or their guardians recorded data in a seizure diary throughout the study. The secondary endpoints were changes in the frequency of generalized seizures, epileptic spasms, and status epilepticus; response rate, which is the percentage of patients showing a ≥50% reduction in the frequency of focal seizure during the maintenance therapy period; proportion of patients who are free from focal seizure during the maintenance therapy period; decreased incidence and response rates of focal seizures at 4, 8, and 12 weeks in the maintenance therapy period; and adverse events. During the study, adverse events were recorded and categorized based on the Common Terminology Criteria for Adverse Events version 4.03. All investigators
completed the Columbia-Suicide Severity Rating Scale training\(^{19}\) prior to the study.

We performed an exploratory investigation of the pharmacokinetics of sirolimus, correlation between combination drugs and pharmacokinetics of sirolimus, degree of decrease in seizure frequency using FCD registration data as the external control group, and changes in blood KL-6 level, which is a chemical marker for pneumonitis (reference range: \(<500\) U/mL),\(^{20}\) and white blood cell and lymphocyte counts at each visit during dose-adjustment period and at 12 weeks in the maintenance therapy period. Blood was also collected at 4 and 8 weeks in the maintenance therapy period if necessary. Next, a prospective cohort study on epileptic seizures associated with FCD type II (RES-FCD, UMIN000033606) was conducted to compare the frequency of seizures between the control and clinical sirolimus-treated groups from August 2018 to September 2020. The same patient selection criteria of the clinical trial (FCDS-01) were adopted to external cohort (RES-FCD). The primary endpoint of RES-FCD was a reduced frequency of focal seizures per 28 days during a 24-week observation period. The secondary endpoints of RES-FCD were similar to those of the clinical trial. The blood testosterone concentrations of male participants aged older than 9 years were investigated in the middle of the study due to the risk of sirolimus-associated male infertility.\(^{21}\)

### Statistical analyses

The sample size was 15, which was based on the feasibility of the study. The study was registered within the given period even if the sample size exceeded 15. To ensure efficacy, two analysis sets were used: full analysis set (FAS) and per protocol set (PPS). FAS was the main analysis set, and it comprised patients who were enrolled and treated with the drug. However, patients who had serious protocol violations, such as the absence of FCDS type II diagnosis or informed consent, and who were not eligible and without any data about seizure after drug administration were excluded from the FAS. Meanwhile, the PPS comprised patients from the FAS who had no serious
protocol violation, met the provision of the clinical trial practice plan, and could be evaluated for efficacy according to the protocol. As for the reduction rate of focal seizures, the Wilcoxon one-sample signed-rank test was used to evaluate the null hypothesis against a median of 0. Moreover, the log-transformed incidence of focal seizures, ratio of the maintenance therapy period to baseline, and 90% confidence interval (CI) were calculated. The response rate and proportion of patients who experienced focal seizure resolution and their 90% CI were examined. In addition, the frequency of focal seizures at baseline and at 4, 8, and 12 weeks was evaluated via a regression analysis with time as a fixed effect and the patient as a random effect, which was based on a negative binomial distribution with the response variable as the frequency of seizures (times/28 days) and the log-transformed observation period as the offset variable. To examine differences in characteristics between the external control and sirolimus-treated groups, the Fisher's exact test and Wilcoxon rank-sum test were used. The propensity score of the groups (sirolimus-treated/control) based on each characteristic was assessed. For the subgroup analysis, we calculated the rate of reduction of focal seizure frequency in patients who did and did not undergo surgery. In addition, changes from baseline in KL-6 were assessed using the one-sample Wilcoxon test. All statistical analyses were conducted using the SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results

Patients

Sixteen patients (aged 7–57 years) were screened, and none dropped out during the baseline phase. One patient (Patient 13) dropped out during the dose-adjustment phase due to the use of prohibited drugs (midazolam and thiopental sodium) for status epilepticus, which had occurred repeatedly before administration of sirolimus. This patient had no data on seizure frequency during the maintenance therapy period; thus, the data were eliminated from the efficacy analysis in FAS. Further, two more patients were excluded from the FAS due to non-compliance and use of prohibited drugs (PPS, \(n = 13\)). However, they were included in the safety analysis. Table 1 shows the demographic and baseline characteristics of individual patients (\(n = 16\)). The patient’s mean age was 16.7 ± 12.1 years (mean ± standard deviation [SD]), and the median age was 13 years. In addition, 13 patients underwent neurosurgery; six and seven of these patients were classified as FCD type IIa and FCD type IIb, respectively. Three patients who did

| Patient No. | Age at study entry (years) | Sex | FCD type | Age at seizure onset (years) | Focal seizure type | Seizure type other than focal seizure | Neurological findings | Cognitive dysfunction |
|-------------|---------------------------|-----|----------|-----------------------------|-------------------|--------------------------------------|----------------------|---------------------|
| 1           | 11                        | M   | IIa      | 0                           | FIAS              |                                      |                      | ID                  |
| 2           | 9                         | M   | IIb      | 4                           | FAwS             |                                      |                      | ADHD                |
| 3           | 21                        | F   | IIa      | 0                           | FIAS              | Tonic, myoclonic                     | Hemiplegia, involuntary movement, sensory disturbance | ID                  |
| 4           | 6                         | F   | IIb      | 0                           | FIAS              |                                      |                      | ID                  |
| 5           | 21                        | F   | II       | 14                          | FIAS              |                                      |                      | ID, personality disorder |
| 6           | 13                        | M   | IIa      | 0                           | FAwS, FIAS       |                                      |                      | ID                  |
| 7           | 24                        | F   | IIb      | 0                           | FIAS              | Tonic, ES                           | Hemiplegia           | ID                  |
| 8           | 7                         | M   | IIa      | 1                           | FAwS, FBTC       | Tonic                               | ID                   | ASD                 |
| 9           | 15                        | M   | IIa      | 7                           | FAwS, FIAS       |                                      |                      | Tics                |
| 10          | 12                        | F   | IIa      | 53                          | FIAS              | Tonic-clonic                        | Sensory disturbance  | ID                  |
| 11          | 12                        | M   | II       | 0                           | FIAS              |                                      |                      | ID, ASD              |
| 12          | 13                        | F   | IIb      | 0                           | FIAS              | ES                                   | Paraplegia, able to sit alone | ID                  |
| 13          | 7                         | F   | IIb      | 1                           | FAwS, FIAS, FBTC | ES                                   | Hemiplegia           | ID                  |
| 14          | 20                        | M   | II       | 9                           | FAwS, FBTC       |                                      |                      | ID                  |
| 15          | 19                        | M   | IIb      | 1                           | FIAS              | Tonic                               |                      | ID                  |

ADHD, attention-deficit/hyperactivity disorder; ASD, autistic spectrum disorder; ES, epileptic spasms; F, female; FAwS, focal awareness seizure; FBTC, focal to bilateral tonic-clonic seizure; FCD, focal cortical dysplasia; FIAS, focal impaired awareness seizure; ID, intellectual disability; M, male.
not undergo neurosurgery presented with FCD type II, which were classified according to brain MRI findings. Patient 11 who had a pathogenic variant of MTOR (NM_004958:c.4448G>A:p.Cys1483Tyr) with a variant allele frequency of 4% in the surgically resected brain tissue atypically experienced her first seizure at 53 years of age. Focal seizure types were classified as focal awareness seizure (n = 7), focal impaired awareness seizure (n = 12), and focal to bilateral tonic–clonic seizure (n = 4). The daily dose during the maintenance therapy period was 2 or 4 mg (Table 2). In three patients, the sirolimus dose was modified during the maintenance period due to appetite loss and somnolence (Patient 4), pneumonitis (Patient 9), and proteinuria (Patient 12). The blood concentrations of sirolimus (mean ± SD) at the 4-, 8-, and 12-week maintenance therapy periods were 5.0 ± 2.1, 4.6 ± 2.6, and 5.0 ± 1.9 ng/mL, respectively. Meanwhile, the concentrations at the dose-adjustment phase and maintenance therapy period did not differ between a combination with and without each concomitant antiepileptic drug.

Efficacy

The median frequency of focal seizures per 28 days at baseline and the maintenance therapy period in the FAS were 24.0 (range: 4.0–1122.0) and 18.2 (range: 0–867.4), respectively. The median reduction rate of focal seizure frequency per 28 days during the maintenance therapy period was 25% (range: −89% to 100%), which was not a substantial change (p = 0.11). The estimated frequency of focal seizures per 28 days was 32.3 (90% CI: 14.8–70.7) at baseline, 23.0 (90% CI: 10.5–50.3) at 1–4 week, 17.4 (90% CI: 7.9–38.2) at 5–8 week, and 19.4 (90% CI: 8.8–42.5) at 9–12 week (Fig. 2). The frequency of focal seizure at the 5–8- and 9–12-week maintenance therapy periods decreased based on the regression analysis (p = 0.003 and 0.013, respectively). Similar results were observed in the PPS. The median frequency of focal seizures per 28 days at baseline and during the maintenance therapy period were 22.0 (range, 4.0–1122.0) and 18.2 (range, 0–867.4), respectively, in the PPS. The median reduction rate of focal seizure frequency per 28 days during the maintenance therapy period was 25% (range, −89% to 100%, p = 0.19). The response rate was 33% (5/15, 90% CI: 14–58%). One patient (Patient 16) was free from seizure during the maintenance therapy period (7%, 90% CI: 0.3–28%). The frequency of generalized seizures per 28 days (mean ± SD) at baseline and during the maintenance therapy period were 5.9 ± 15.69 (range: 0–47) and 2.5 ± 9.3 (range: 0–36), respectively. None of the patients showed epileptic spasms or status epilepticus at baseline or during the maintenance therapy period.

Comparison between the external control and sirolimus-treated groups

Figure 3 shows changes in seizure frequency in each participant of the external control and sirolimus-treated groups. The distribution of background characteristics of the external control group (RES-FCD) versus the sirolimus-treated group differed (Table 3). In the two groups, sampling bias (p < 0.15) affected age and frequency of focal seizures, epileptic spasms, sensory disturbance, and surgical intervention. The propensity score based on age, age at disease onset, baseline frequency of focal seizures, and surgery differed between the external control and sirolimus-treated groups (median [interquartile range] of 0.02 [0.01–0.16] and 0.67 [0.32–0.77]). Because comparability could not be guaranteed, we did not estimate the difference in the reduction rate of focal seizure frequency between the two groups. However, the median reduction rates for the external control and sirolimus-treated groups were 0.5% and 25%, respectively. In the subgroup analysis of patients who did and did not undergo surgery, the median rate of reduction of focal seizure frequency for the external control and sirolimus-treated groups were 0% (n = 19) and 25% (n = 13) in patients who underwent surgery and 5% (n = 41) and 10% (n = 2) in patients who did not undergo surgery, respectively.

Safety

All patients presented with adverse events (Table 4, Table S3). Three patients experienced severe adverse events, such as epileptic seizure (twice in Patient 10), head skin tear due to head trauma associated with seizure attack (Patient 11), and gastroenteritis due to Norovirus infection at the 9th day of dose-adjustment phase and status epilepticus at the 44th day of dose-adjustment phase (Patient 13). All severe adverse events were supposed to be irrelevant for sirolimus, and the patients completely recovered. The median blood KL-6 level (U/L) was 170.5 (n = 16, range: 129–501) at baseline, and it increased to 185 (n = 15, range: 117–702, p = 0.094), 243 (n = 15, range: 146–867, p < 0.001), and 243 (n = 13, range: 141–1158, p = 0.001) at week 4 of the dose-adjustment phase, just before the maintenance therapy period and at week 12 of the maintenance therapy period, respectively (Fig. 4). Patient 3 and 7 had KL-6 above 500 U/mL. However, they did not develop pneumonitis. Patient 9 had grade 2 pneumonitis during the maintenance therapy period. Thus, treatment with sirolimus was discontinued for 4 days, during which the KL-6 levels increased from 320 at baseline to 432 at week 12 of the maintenance therapy period.
| Patient no. | Daily dose during maintenance therapy (mg) | Blood concentration of sirolimus at 4, 8, and 12 weeks of maintenance therapy (ng/mL) | Focal seizure frequency at baseline (per 28 days) | Focal seizure frequency during maintenance therapy (per 28 days) | Reduction rate of focal seizures (%) |
|-------------|--------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------|----------------------------------|
| 1           | 4                                         | 78.2                                                                               | 60.9                                          | 15.61                                            | 0–4 weeks: 2.29 5–8 weeks: 15.61 9–12 weeks: 69.5 |
| 2           | 4                                         | 80                                                                                 | 66                                            | 0–4 weeks: 15.61 5–8 weeks: 69.5 9–12 weeks: 110.4 |
| 3           | 4                                         | 18.2                                                                               | 16.8                                          | 22.63                                            | 0–4 weeks: 4.52 5–8 weeks: 11.17 9–12 weeks: 1.29 |
| 4           | 10.6                                      | 254.9                                                                              | 212.7                                         | 23.62                                            | 0–4 weeks: 3.63 5–8 weeks: 25.95 9–12 weeks: 2.87 |
| 5           | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 6           | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 7           | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 8           | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 9           | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 10          | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 11          | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 12          | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 13          | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 14          | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 15          | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |
| 16          | 12                                         | 1 /blood concentration C0                                                        | 15.61                                         | 10.6                                             | 0–4 weeks: 1.69 5–8 weeks: 3.76 9–12 weeks: 3.9 |

One day after the end of week 12.

© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Discussion

In this trial, the reduction of focal seizures did not meet the predetermined level of statistical significance. However, focal seizure frequency reduced over time in sirolimus-treated patients. The efficacy of this drug in patients with FCD type II (response rate, 33.3%) was comparable to that of everolimus, another mTOR inhibitor, for treatment-resistant seizures in patients with TSC.22

The average trough level of sirolimus was relatively lower than the anticipated value during the maintenance therapy period. There was no difference in terms of trough levels between five responders (5.2 ± 1.6 ng/mL) and 10 nonresponders (4.9 ± 2.1 ng/mL). Everolimus had a dose or blood level-dependent effect against seizure in patients with TSC, with a response rate of 28.2% for a low-trough level (3–7 ng/mL) and 40.0% for a high-trough level (8–15 ng/mL).23 The administration of sirolimus at a higher dose might be beneficial for reducing seizure frequency in patients with FCD type II.

We included an FCD cohort (RES-FCD) and collected clinical information from 60 patients who were included in the control group. The two groups differed in terms of background characteristics, thereby affecting the prognosis of seizures and comorbidities.23,24 More frequent focal seizures in the sirolimus-treated group suggest a higher disease severity than that in the control group.

All patients developed adverse events during the study period. The safety profile of this study was consistent with that of previous studies of patients treated with sirolimus or everolimus.25,26 Stomatitis was the most common adverse event as known well. The frequency of stomatitis is gradually decreasing over time,27 and none of our
Figure 3. Percentage change in the frequency of focal seizures from baseline. Each bar represents one patient in the sirolimus-treated group (A) and the external control group (B).
The age of seizure onset was unknown in Patient 10, who was then excluded.

### Table 3. Comparison of demographic characteristics between the external control and sirolimus-treated groups.

| Sex        | Controls n = 60 | FCDS-01 n = 15 | p value |
|------------|-----------------|----------------|---------|
| Male       | 25 (42%)        | 8 (53%)        | 0.56    |
| Female     | 35 (58%)        | 7 (47%)        |         |
| Age (years)|                |                |         |
| Average ± standard deviation | 23.9 ± 13.51 | 16.9 ± 12.49 | 0.04    |
| Median     | 22.5            | 13             |         |
| Minimum–maximum | 6–59       | 6–57           |         |
| The age of onset |            |                |         |
| Average ± standard deviation | 5.7 ± 5.88  | 6.4 ± 14.08¹  | 0.28    |
| Median (minimum–maximum) | 3 (0–20)   | 1 (0–53)       |         |
| Seizure type|                |                |         |
| Focal awareness seizure | 24 (40%)   | 7 (47%)        | 0.77    |
| Focal impaired awareness seizure | 40 (67%) | 12 (80%)      | 0.37    |
| Focal to bilateral tonic–clonic seizure | 28 (47%)  | 6 (40%)        | 0.78    |
| Myoclonic seizure | 0 (0%)     | 1 (7%)         | 0.20    |
| Tonic seizure | 8 (13%)     | 4 (27%)        | 0.24    |
| Tonic–clonic seizure | 7 (12%)   | 1 (7%)         | 1.00    |
| Epileptic spasms | 1 (2%)     | 2 (13%)        | 0.10    |
| Seizure frequency |            |                |         |
| Baseline frequency of focal seizures per 28 days | 22.2 ± 41.8 | 134.8 ± 299.51 | 0.03 |

### Neurological findings

| Cognitive dysfunction | Controls grade 1 | FCDS-01 grade 1 | p value |
|-----------------------|------------------|-----------------|---------|
| Intellectual disability | 30 (50%) | 10 (67%) | 0.39 |
| ASD | 8 (13%) | 2 (13%) | 1.00 |
| ADHD | 0 (0%) | 1 (7%) | 0.40 |
| Others | 1 (2%) | 2 (13%) | 0.20 |

### Treatments other than sirolimus

| Pharmacotherapy | Controls grade 1 | FCDS-01 grade 1 | p value |
|-----------------|------------------|-----------------|---------|
| ACTH | 3 (5%) | 2 (13%) | 0.26 |
| Surgery | 19 (32%) | 13 (87%) | <0.001 |
| Lesionectomy/lobectomy | 17 (28%) | 9 (60%) |         |
| Multilobectomy | 1 (2%) | 4 (27%) |         |
| Callosotomy | 0 (0%) | 2 (13%) |         |
| Vagus nerve stimulation | 1 (2%) | 2 (13%) |         |

The p value was calculated using the Wilcoxon signed-rank test for sex and the Fisher’s exact test for others. ACTH, adrenocorticotropic hormone; ADHD, attention-deficit/hyperactivity disorder; ASD, autistic spectrum disorder; n, number.

¹The age of seizure onset was unknown in Patient 10, who was then excluded.

patients required discontinuation of treatment in this short-term trial. The second most frequent adverse event was infection, and it is the most common cause of treatment discontinuation in severe cases.²⁸ Notably, pneumonitis is a serious side effect of mTOR inhibitors.²⁹ The blood KL-6 level was elevated over time. Hence, patients treated with sirolimus must be continually monitored.

Only one patient underwent mutation analysis. Somatic activating mutations in MTOR are most commonly associated with FCD type II.⁵,¹⁰ Considering the pharmacological effect of sirolimus and elevated mTOR function, patients with FCD caused by a pathogenic variant of MTOR or other MTOR-related genes respond more efficiently to sirolimus than those with condition not related to elevated mTOR function. Mutation analysis of brain tissue, which should ideally be performed prior to sirolimus treatment, is not always possible. FCD is mainly caused by a somatic mosaic mutation with low-frequency mutant allele, which requires deep sequencing for detection, and samples of pathological brain tissues are needed for examination. In terms of practical use, the diagnosis of FCD type II would be a minimum requirement for selecting patients eligible for sirolimus.

Most patients with FCD experience their first seizure within the first 5 years.¹ However, the age limit was decreased to accommodate children aged 6 years in the trial, with consideration of their average weight, which is about 20 kg. This can ensure that a starting dose of 1 mg/day can be administered safely, and children aged about 6 years can take tablets. Sirolimus is used for younger patients to prevent allograft rejection after kidney transplant³⁰ or to treat complicated vascular anomalies.³¹ As indicated by the association between early-onset or intractable frequent seizures and cognitive anomalies in patients with FCD,²⁴ additional studies about treatment...
for seizures in FCD patients aged younger than 6 years must be performed.

The current study has several limitations. That is, a placebo group was not included. The background characteristics of external control and sirolimus-treated groups, including the proportion of patients with pathology-proven FCD type II, differed. Moreover, the number of participants were limited, and the trial duration was relatively short. In total, 12 patients, including two from the preceding proof-of-concept study (manuscript submitted), received continuous sirolimus treatment in the extension trial. However, further investigations must be performed to confirm the efficacy and safety of short- and long-term treatment with sirolimus.

In conclusion, the reduction of focal seizures did not meet the predetermined level of statistical significance. The safety profile of the drug was tolerable. The potential for a reduction of focal seizures over time merit further investigations in large and long-term trials.

Acknowledgments

The authors thank the patients and families for their participation in the present clinical trial. The authors also thank Dr. Chizuru Ikeda at NHO Kumamoto Saishun Medical Center and Dr. Tatsuharu Sato at Nagasaki University Hospital for patient recruitment. This study was supported by grants from the Project Promoting Clinical Trials for Development of New Drugs from the Japan Agency for Medical Research and Development (20lk0201069h0004), Grant-in-Aid for Scientific Research–KAKENHI (C) from the Japan Society for the Promotion of Science (20K08236) to M. K., and a grant from the Ministry of Health, Labor, and Welfare (JPMH20FC1039) to M. K. and Y. I. Nobelpharma Co., Ltd. provided the investigational drug and was responsible for the delivery of the drug but had no role in study design or conduct. Other funders, including Nobelpharma Co., Ltd., had no role in data
collection, interpretation, and analyses or writing of the manuscript.

Author Contributions
M. K. contributed to the conception of the study; M. K., A. Kada, J. T., and A. M. S. contributed to the design of the study; M. K. and A. Kada contributed to the analysis of data and drafting the text or preparing figures; A. Kada contributed to statistical analysis; H. S., J. T., E. N., Y. T., and T. A. contributed to enrollment of the patient and collection and analysis of clinical data; A. Kakita contributed to neuropathological diagnosis; N. M. and A. F. contributed to molecular analysis; A. M. S. contributed to the management of data; Y. I. contributed to the design of the external cohort study.

Conflict of Interests
Y. T. received academic donation from Eisai. A. Kada, who is a member of the independent data monitoring committee of clinical trials, received personal fees from Bayer Yakuhin, Ltd. outside the submitted work. The other authors have no conflict of interest to disclose.

Data Availability
De-identified individual participant data (including data dictionaries) in addition to study protocols, statistical analyses, and informed consent forms will be made available upon publication to researchers who provide a methodologically sound proposal for the use of data. Proposals should be submitted to ktmthr@gmail.com.

References
1. Fauser S, Huppertz HJ, Bast T, et al. Clinical characteristics in focal cortical dysplasia: a retrospective evaluation in a series of 120 patients. Brain. 2006;129:1907-1916.
2. Guerrini R, Duchowny M, Jayakar P, et al. Diagnostic methods and treatment options for focal cortical dysplasia. Epilepsia. 2015;56:1669-1686.
3. Fauser S, Essang C, Altemuller DM, et al. Long-term seizure outcome in 211 patients with focal cortical dysplasia. Epilepsia. 2015;56:666-76.
4. Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med. 2015;21:395-400.
5. Nakashima M, Saito H, Takei N, et al. Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann Neurol. 2015;78:375-386.
6. Jansen LA, Mirzaa GM, Ishak GE, et al. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. Brain. 2015;138(Pt 6):1613-1628.
7. Mirzaa GM, Campbell CD, Solovieff N, et al. Association of MTOR mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmentary mosaicism. JAMA Neurol. 2016;73:836-845.
8. Lim JS, Gopalappa R, Kim SH, et al. Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia. Am J Hum Genet. 2017;100:454-472.
9. D’Gama AM, Woodworth MB, Hossain AA, et al. Somatic mutations activating the mTOR pathway in dorsal telencephalic progenitors cause a continuum of cortical dysplasias. Cell Rep. 2017;21:3754-3766.
10. D’Gama AM, Walsh CA. Focal cortical dysplasia. In Rubenstein J, Rakic P, Chen B, Kwan KY, eds. Neurodevelopmental Disorders. Elsevier; 2020:285-307.
11. Palmini A, Gambardella A, Andermann F, et al. Intrinsic epileptogenicity of human dysplastic cortex as suggested by corticography and surgical results. Ann Neurol. 1995;37:476-487.
12. Varotto G, Tassi L, Franceschetti S, Spreafico R, Panzica F. Epileptogenic networks of type II focal cortical dysplasia: a stereo-EEG study. Neuroimage. 2012;61:591-598.
13. Ostendorf AP, Wong M. mTOR inhibition in epilepsy: rationale and clinical perspectives. CNS Drugs. 2015;29:91-99.
14. Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 2014;164:1195-1200.
15. Xu Q, Ulile-Sibony S, Dunham C, et al. mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report. J Child Neurol. 2019;34:132-138.
16. Kada A, Toyohama J, Shiromaish H, et al. A single-arm open-label clinical trial on the efficacy and safety of sirolimus for epileptic seizures associated with focal cortical dysplasia type II: a study protocol. Kurume Med J. 2019;66:115-120.
17. Colombo N, Salamon N, Raybaut C, Oskara C, Barkovich AJ. Imaging of malformations of cortical development. Epileptic Disord. 2009;11:194-205.
18. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia. 2011;52:158-174.
19. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.
20. Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58:872-875.
21. Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant. 2008;8:1471-1479.
22. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153-2163.
23. D’Argenzio L, Colonnelli MC, Harrison S, et al. Cognitive outcome after extratemporal epilepsy surgery in childhood. Epilepsia. 2011;52:1966-1972.
24. Kimura N, Takahashi Y, Shigematsu H, et al. Risk factors of cognitive impairment in pediatric epilepsy patients with focal cortical dysplasia. Brain Dev. 2019;41:77-84.
25. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014;28:126-133.
26. Krueger DA, Capal JK, Curatolo P, et al. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): multicentre clinical experience. Eur J Paediatr Neurol. 2018;22:1066-1073.
27. Felix MJ, Felipe CR, Tedesco-Silva H, Osmar M-PJ. Time-dependent and immunosuppressive drug-associated adverse event profiles in de novo kidney transplant recipients converted from tacrolimus to sirolimus regimens. Pharmacotherapy. 2016;36:152-165.
28. Sanchez-Fructuoso AI, Ruiz JC, Perez-Flores I, Gomez Alamillo C, Calvo Romero N, Arias M. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc. 2010;42:3050-3052.
29. Duran I, Goebell PJ, Papazisis K, et al. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf. 2014;13:361-372.
30. Gonzalez D, Garcia CD, Azocar M, et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol. 2011;26:961-966.
31. Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57:1018-1024.

**Supporting Information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Table S1.** Distribution of the causative genes in patients with each type of focal cortical dysplasia or hemimegalencephaly.

**Table S2.** Previous trials for epileptic seizures treated with mTOR inhibitors.

**Table S3.** All adverse events reported in patients receiving sirolimus.